Bra tattoo changed woman's life after breast cancer
A 69-year-old breast cancer survivor gets her confidence back after having a bra tattoo.
Caiyun Li, Hongyan Liu, Yunqing Yang, Xixi Xu, Tongtong Lv, Huidan Zhang, Kehang Liu, Shuangquan Zhang, Yuqing Chen
ConclusionsThe use of time-to-death statistics to display mortality benefits for treated versus untreated women helps facilitate the distinction between treatments which increase the likelihood of cure and treatments that delay cancer growth.
ConclusionThe article concludes by highlighting the major economic impact associated with breast cancer deaths and by pointing out future research areas.
AbstractPurposeThe extracellular domain (ECD) of human epidermal growth factor receptor-2 (HER2) in the blood is a promising biomarker of cancer prognosis and response to therapy, whereas the clinical prognostic role of serum HER2 ECD (sHER2 ECD) level in patients with BC remains controversial. Moreover, its cut-off value significantly varies. Thus, this meta-analysis aimed to quantify the prognostic impact of this biomarker with a specific cut-off value in patients with BC.MethodsA systematic review of electronic databases was conducted to identify studies that assessed the association between baseline sHER2 ECD level wit...
This report summarizes the voting questions and resulting percentages of answers of the Egyptian scientists. Interestingly the differences were minimal between the Cairo and original Saint Gallen Consensus denoting a more global view of breast cancer management all over the world.
ConclusionsCollaborative studies are required so that men can participate in meaningful RCTs to provide an evidence-based rational foundation for the surgery of MBC.
This study aimed to develop mathematical tools to predict the likelihood of recurrence after neoadjuvant chemotherapy (NAC) plus trastuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer.MethodsData of 776 patients from a multicenter retrospective cohort study were collected. All patients had HER2-positive breast cancer and received NAC plus trastuzumab between 2001 and 2010. Two mathematical tools using a machine learning method were developed to predict the likelihood of disease-free survival (DFS) (DFS model) and brain metastasis (BM) (BM model) within 5 years after surger...
ConclusionsThe copy number variation initially recognized as duplication of exon 1 –19 of theBRCA1 gene by MLPA analysis is a structural variation with breakpoints in theBRCA1 andDHX8 genes. Although currently to be classified as a variant of unknown significance, our family data indicates that this duplication may be a benign variation or at least of markedly reduced penetrance since it occursin trans with another known fully pathogenic variant in theBRCA1 gene.